Intervention
Nicotinamide riboside
Research Observatory
Evidence Update
Current evidence
Nicotinamide riboside (NR) findings differ by population: muscle/metabolic nulls coexist with a preliminary walking signal in peripheral artery disease.
What changed
Adds the obese-men metabolic report and NICE, including its one-sided .10 threshold.
What did not change
No general rejuvenation or longevity benefit; earlier muscle-null conclusions remain.
Why it matters
Target engagement and disease-specific function answer different questions.
Main limitation
Small trials; some abstract-only sources; NICE is not conventional two-sided .05 confirmation.
Next proof
Confirmatory disease-specific functional trials.
Summary
NR findings differ by population: muscle/metabolic nulls coexist with a preliminary PAD walking signal.
Intelligence Take
Target engagement and disease-specific function answer different questions.
Limitations
Small trials; some abstract-only sources; NICE is not conventional two-sided .05 confirmation.